BLTE Belite Bio, Inc.
$151.02
Belite Bio, Inc. (BLTE) Earnings News
Earnings press releases, previews and reviews for Belite Bio, Inc. (BLTE), newest first. Our most recent is review: Belite Bio Beats on the Bottom Line as FDA Path for Tinlarebant Clears, but Slipping GA Timelines and Rising Launch Spend Leave Investors Souring.
Thursday
November 12, 2026
6:43 PM ET
Belite Bio Beats on the Bottom Line as FDA Path for Tinlarebant Clears, but Slipping GA Timelines and Rising Launch Spend Leave Investors Souring
Earnings Whispers · Review
Thursday
November 12, 2026
6:00 AM ET
Belite Bio Reports Unaudited Third Quarter 2026 Financial Results and Provides a Corporate Update
Thursday
November 5, 2026
12:12 PM ET
Belite Bio's Pre-Launch Spending Faces Scrutiny as February FDA Decision on Tinlaraban Nears
Earnings Whispers · Preview
Thursday
November 5, 2026
8:00 AM ET
Belite Bio to Host Webcast on November 12, 2026, to Discuss Third Quarter 2026 Financial Results
Wednesday
August 12, 2026
9:45 PM ET
Belite Bio Reports Unaudited Second Quarter 2026 Financial Results and Provides a Corporate Update
Thursday
August 6, 2026
8:00 AM ET
Belite Bio to Host Webcast on August 13, 2026, to Discuss Second Quarter 2026 Financial Results